Solid Biosciences · 16 hours ago
Senior Director, Opinion Leader Programming
Charlestown, MA, US
Full-time
Onsite
Director/Executive
$262K/yr - $295K/yr
10+ years expSolid Biosciences is a precision genetic medicine company focused on advancing gene therapy candidates for rare diseases. The Senior Director of Opinion Leader Programming will lead the development and execution of the company's opinion leader engagement strategy, building relationships with external experts and ensuring alignment with corporate objectives.
BiotechnologyGeneticsHealth CareMedical
Responsibilities
Define and lead the strategy for opinion leader programming across pre-launch, launch, and post-launch phases
Design and implement a structured approach for identifying, segmenting, and engaging KOLs and other key stakeholders
Lead the planning, execution, and follow-up of advisory boards, roundtables, and other strategic engagement forums
Build the opinion leader programming field-facing roles to support KOL engagement including defining structure, focus, and deployment plan
Develop content and materials to support field team engagement with external experts with collaboration from Medical Affairs and Commercial teams
Align medical communications with corporate and field engagement strategies, ensuring consistency and scientific integrity
Build and maintain systems for capturing insights from KOL interactions to inform internal strategy
Partner with cross-functional teams including Clinical Development, Account Mangers, and Medical Affairs to support a unified external engagement approach
Serve as a key internal advisor on thought leader dynamics, competitive landscape, and scientific communication best practices
Qualification
Required
Bachelor's degree in life sciences or related field required
Minimum of 10 years of relevant experience in the biotechnology or pharmaceutical industry, including medical affairs, commercial strategy, or medical communications
Experience developing and executing KOL engagement strategies and programming at a national or global level
Strong understanding of industry compliance and regulatory standards related to external engagement
Demonstrated success leading cross-functional teams and delivering high-impact external programming
Significant travel required as needed, including attendance at scientific congresses, advisory boards, and field engagement meetings
Strong strategic and tactical planning skills
Excellent communication and interpersonal skills, with the ability to create impactful content and messaging
Proven ability to manage advisory boards and expert engagement initiatives
Deep understanding of field medical and commercial collaboration dynamics
Strong organizational and cross-functional leadership skills
Ability to influence across diverse teams and senior leadership
Comfortable operating in a fast-paced, evolving environment
Preferred
advanced degree (PharmD, PhD, MD, or MBA)
Prior work in rare disease, gene therapy, or advanced biologics
Benefits
Competitive Health and Dental programs with flexible plan offerings, including FSA and HSA programs
401(k) program participation with competitive company matched contributions
Eligibility to participate in Solid’s Employee Stock Purchase Plan
Mobile phone subsidy for eligible employees
Tuition Reimbursement
Vision Coverage
Life Insurance
Voluntary Pet Insurance
Employee Discount Program on Travel, Entertainment, and Services
Employee Assistance Programs
Daily Subsidized Lunch Delivery (onsite @ Hood Park)
Free Onsite Full-Service Gym (onsite @ Hood Park)
Employee Parking (onsite @ Hood Park)
12 Observed Holidays and a winter shut down
15-day PTO Policy and a 40-hour rollover YoY
40-hour Sick Policy
8 Hour Floating Holiday
Company
Solid Biosciences
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$810.3MKey Investors
Ultragenyx PharmaceuticalPerceptive AdvisorsJP Morgan
2025-02-18Post Ipo Equity· $200M
2024-01-08Post Ipo Equity· $109M
2022-09-30Post Ipo Equity· $75M
Leadership Team
Alexander Cumbo
CEO and President
Kevin Tan
Chief Financial Officer
Recent News
Pharmaceutical Technology
2026-01-16
Company data provided by crunchbase